Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles These Are Institutional Investor’s 2026 Hedge Fund Rising Stars For Members Only Inside Viking’s Hybrid Strategy for Investing Across Public and Private Markets Stephen Taub How Nonprofits of Varying Sizes Can Tap Into Big-firm Investment Expertise Sponsored by Fidelity Investments